Disposition of tradable shares by Zannes Maria of BioAffinity Technologies subject to Rule 16b-3

BIAFW Stock  USD 0.60  0.03  5.26%   
Slightly above 55% of BioAffinity Technologies' sophisticated investors are presently thinking to get in. The analysis of the overall investor sentiment regarding bioAffinity Technologies Warrant suggests that some traders are interested. BioAffinity Technologies' investing sentiment can be driven by a variety of factors including economic data, BioAffinity Technologies' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by bioAffinity Technologies Warrant Officer: President, Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
BioAffinity insider trading alert for disposition of common stock, par value $0.007 by Zannes Maria, Officer: President, Ceo, on 19th of September 2024. This event was filed by bioAffinity Technologies Warrant with SEC on 2022-08-29. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

BioAffinity Technologies' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the BioAffinity Technologies' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

BioAffinity Technologies Fundamental Analysis

We analyze BioAffinity Technologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAffinity Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Operating Margin

Operating Margin Comparative Analysis

BioAffinity Technologies is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

BioAffinity Technologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioAffinity Technologies stock to make a market-neutral strategy. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics with similar companies.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.